Swoop Creates Patient Advocacy and Privacy Advisory Board

Advisors to guide company’s patient outcomes-driven technology development

CAMBRIDGE, MA. – May 16, 2019 – Swoop, the company driving better patient outcomes through AI-generated digital audiences for the life sciences industry, today announced a newly-formed Patient Advocacy and Privacy Advisory Board. The formation of the Board empowers Swoop to continue being at the forefront of using the constantly-improving power of AI and digital messaging for patient engagement while protecting consumer rights and lowering healthcare costs.

Members of the Board include: Patricia Bailin, Head of Privacy and Data Ethics of Datavant, previously a Privacy Officer for LiveRamp and the Director of Privacy for Product and Engineering at Acxiom; Jennifer Beachell – former President of US Commercial at Aegerion Pharmaceuticals, VP of Marketing and Market Access at Welldoc; and Jodie Sherman Gillon – Global Medical Lead, Patient Engagement Rare Diseases, Pfizer.

“The ability of data-driven technology companies to predict and shape patient outcomes creates both an opportunity and a responsibility to uphold and protect patient and consumer privacy”, said Patricia Bailin. “The lack of regulatory and guidelines in this emerging area complicates matters, as questions such as “What is a positive patient outcome, and who sets the standard?”, “What data is acceptable to use in order to make predictions, and who decides?” exist in a grey area with no clearly defined answers”.

“Developing criteria for determining sensitive health conditions where advertising requires consumer opt-in consent allows Swoop to help shape an environment where consumers are provided with clear notice and choice,” said Jennifer Beachell. “We believe that this is the best way to integrate strong privacy protections with ethical and effective use of artificial intelligence for the benefit of consumers, the biopharma industry and society as a whole.

Swoop has invested significant resources and effort to improve patient outcomes without sacrificing patient privacy building on our founders’ work with Evidon/Ghostery, the first system designed to give consumers control over their online data and choices; our participation as founding members of TAG, the Trustworthiness Accountability Group; our involvement with IAB’s Data Transparency Standards Working Group; our participation in the Health Working Group at the Future of Privacy Forum; and the development of our best-in-class HIPAA-certified privacy platform.

About Swoop

Swoop empowers the world’s leading pharmaceutical brands to better-educate patients about disease states and the therapies that could remedy their conditions, as well as enable them to become active participants in their treatment journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement uncovers unique target audiences for precisely activating patient populations and their healthcare ecosystems through cross-channel marketing strategies. By utilizing artificial intelligence in conjunction with a real-world evidence and outcomes research data universe of over 300 million de-identified patient journeys over ten years and 65 billion anonymous consumer interactions, Swoop's patient segments are superior in audience quality, lead to optimal conversion, and drive increased Rx lift.